Table 3.

Ongoing phase-III trials of molnupiravir.

Registered No.	Participants	Study Site	Study Design *	Primary Outcome *	Reference
NCT04575597	1850 non-hospitalized adults with mild or moderate COVID-19	The United States, Canada, Brazil, Mexico, Chile, Colombia, Japan, Taiwan, Philippines, Israel, Germany, France, Poland, Spain, Sweden, United Kingdom, Russian, Ukraine, South Africa (total 141 locations)	Double-blind, randomized-controlled, multicenter	1. Time-to-sustained recovery (up to 29 days); 2. Percentage of participants experiencing adverse events (up to 7 months); 3. Percentage of withdrawal participants due to adverse events (up to 6 days).	[34]
NCT04575584	304 hospitalized adults with mild, moderate, or severe COVID-19	The United States, Canada, Brazil, Mexico, Chile, Colombia, South Korea, Philippines, Israel, France, Poland, Spain, United Kingdom, Russian, Ukraine, South Africa (total 89 locations)			[34]

* The similarity of study design and primary outcome in two trials was noticed.